Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Mark Bustoros, MD, Omar Nadeem, Adam S Sperling, Giada Bianchi, Lily Ardente, Robert A. Redd, Julia Prescott, Erin Frey, Kathleen Guimond, Rachel Styles, Kalvis Hornburg, Alexandra Savell, Nang Kham Su, Govind Bindra, Cody J Boehner, Kaitlen Reyes, Houry Leblebjian, Diane Warren, Nikhil C. Munshi, Jacob P. Laubach, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Institutions: Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4206979142